Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.
Oppenheimer Downgrades Fate Therapeutics to Perform
Oppenheimer analyst Matthew Biegler downgrades Fate Therapeutics (NASDAQ:FATE) from Outperform to Perform.
Related Posts
Why Canopy Growth (CGC) Shares Are Tanking Friday
Canopy Growth Corporation (NASDAQ: CGC) shares are tanking on Friday after the company announced a deal with certain noteholders to acquire CA$12.5 million ($9.4 million) worth of notes in exchange for
Inozyme Pharma Posts Encouraging Data From Rare Calcification Disorders
Inozyme Pharma Inc (NASDAQ: INZY) announced interim safety, pharmacokinetic (PK), pharmacodynamic (PD), and exploratory efficacy data from its ongoing Phase 1/2 trials of INZ-701 in adults with